GHK-Cu stimulates fibroblasts to produce vascular endothelial growth factor (VEGF), the primary signal for new blood vessel formation
Phase (approx.) Cagrilintide dose Frequency Weeks 14 0.25 mg Once weekly Weeks 58 0.5 mg Once weekly Weeks 912 1.0 mg Once weekly Weeks 1316 1.7 mg Once weekly Week 17 onward 2.4 mg (max studied) Once weekly This step-wise schedule mirrors the titration used in cagrilintide and CagriSema studies ( Lau et al., Lancet 2021
Furthermore, throughout the treatment, patients may experience other symptoms, such as nausea, vomiting, lack of appetite, hormonal fluctuations, sleep disturbances, alterations in taste, and changes in skin color (Rana et al., 2017
These markers encompass a range of biochemical abnormalities, such as altered ratios of mtDNA to nuclear DNA, and aberrant expression of mitochondrial inner membrane and matrix proteins [81,90]